These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 30064482)

  • 1. Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44+ cancer stem cells to 5 azacytidine in hepatocellular carcinoma.
    Gao X; Sheng Y; Yang J; Wang C; Zhang R; Zhu Y; Zhang Z; Zhang K; Yan S; Sun H; Wei J; Wang X; Yu X; Zhang Y; Luo Q; Zheng Y; Qiao P; Zhao Y; Dong Q; Qin L
    J Exp Clin Cancer Res; 2018 Jul; 37(1):179. PubMed ID: 30064482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
    Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
    Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway.
    Cao L; Fan X; Jing W; Liang Y; Chen R; Liu Y; Zhu M; Jia R; Wang H; Zhang X; Zhang Y; Zhou X; Zhao J; Guo Y
    Oncotarget; 2015 Mar; 6(9):6627-40. PubMed ID: 25749383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The osteopontin-CD44 axis in hepatic cancer stem cells regulates IFN signaling and HCV replication.
    Shirasaki T; Honda M; Yamashita T; Nio K; Shimakami T; Shimizu R; Nakasyo S; Murai K; Shirasaki N; Okada H; Sakai Y; Sato T; Suzuki T; Yoshioka K; Kaneko S
    Sci Rep; 2018 Sep; 8(1):13143. PubMed ID: 30177680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner.
    Phillips RJ; Helbig KJ; Van der Hoek KH; Seth D; Beard MR
    World J Gastroenterol; 2012 Jul; 18(26):3389-99. PubMed ID: 22807608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ELK3 promotes the migration and invasion of liver cancer stem cells by targeting HIF-1α.
    Lee JH; Hur W; Hong SW; Kim JH; Kim SM; Lee EB; Yoon SK
    Oncol Rep; 2017 Feb; 37(2):813-822. PubMed ID: 27959451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteopontin induces autophagy to promote chemo-resistance in human hepatocellular carcinoma cells.
    Liu G; Fan X; Tang M; Chen R; Wang H; Jia R; Zhou X; Jing W; Wang H; Yang Y; Yin F; Wei H; Li B; Zhao J
    Cancer Lett; 2016 Dec; 383(2):171-182. PubMed ID: 27702661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α pathway.
    Lai FB; Liu WT; Jing YY; Yu GF; Han ZP; Yang X; Zeng JX; Zhang HJ; Shi RY; Li XY; Pan XR; Li R; Zhao QD; Wu MC; Zhang P; Liu JF; Wei LX
    Cancer Lett; 2016 Aug; 378(2):131-41. PubMed ID: 27208741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isovitexin reduces carcinogenicity and stemness in hepatic carcinoma stem-like cells by modulating MnSOD and FoxM1.
    Cao X; Liu L; Yuan Q; Li X; Cui Y; Ren K; Zou C; Chen A; Xu C; Qiu Y; Quan M; Zhang J; Cao J; Chen X
    J Exp Clin Cancer Res; 2019 Jun; 38(1):264. PubMed ID: 31208440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Casticin inhibits stemness of hepatocellular carcinoma cells via disrupting the reciprocal negative regulation between DNMT1 and miR-148a-3p.
    Li X; Wang L; Cao X; Zhou L; Xu C; Cui Y; Qiu Y; Cao J
    Toxicol Appl Pharmacol; 2020 Jun; 396():114998. PubMed ID: 32268151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
    Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
    Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A positive feedback loop between Periostin and TGFβ1 induces and maintains the stemness of hepatocellular carcinoma cells via AP-2α activation.
    Chen G; Wang Y; Zhao X; Xie XZ; Zhao JG; Deng T; Chen ZY; Chen HB; Tong YF; Yang Z; Ding XW; Guo PY; Yu HT; Wu LJ; Zhang SN; Zhu QD; Li JJ; Shan YF; Yu FX; Yu ZP; Xia JL
    J Exp Clin Cancer Res; 2021 Jun; 40(1):218. PubMed ID: 34193219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-C chemokine receptor type 1 mediates osteopontin-promoted metastasis in hepatocellular carcinoma.
    Zhu Y; Gao XM; Yang J; Xu D; Zhang Y; Lu M; Zhang Z; Sheng YY; Li JH; Yu XX; Zheng Y; Dong QZ; Qin LX
    Cancer Sci; 2018 Mar; 109(3):710-723. PubMed ID: 29285854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCN3 is a therapeutic target relating enhanced stemness and coagulation in hepatocellular carcinoma.
    Jia Q; Xue T; Zhang Q; Cheng W; Zhang C; Ma J; Bu Y; Yu S; Liu Q
    Sci Rep; 2017 Oct; 7(1):13846. PubMed ID: 29061995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
    Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
    BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FAM83D associates with high tumor recurrence after liver transplantation involving expansion of CD44+ carcinoma stem cells.
    Lin B; Chen T; Zhang Q; Lu X; Zheng Z; Ding J; Liu J; Yang Z; Geng L; Wu L; Zhou L; Zheng S
    Oncotarget; 2016 Nov; 7(47):77495-77507. PubMed ID: 27769048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma.
    Zhu Z; Hao X; Yan M; Yao M; Ge C; Gu J; Li J
    Int J Cancer; 2010 May; 126(9):2067-78. PubMed ID: 19711346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells.
    Lan X; Wu YZ; Wang Y; Wu FR; Zang CB; Tang C; Cao S; Li SL
    Int J Mol Med; 2013 Feb; 31(2):315-24. PubMed ID: 23233126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model.
    Zhang KZ; Zhang QB; Zhang QB; Sun HC; Ao JY; Chai ZT; Zhu XD; Lu L; Zhang YY; Bu Y; Kong LQ; Tang ZY
    J Hematol Oncol; 2014 Mar; 7():28. PubMed ID: 24678763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta.
    You H; Ding W; Rountree CB
    Hepatology; 2010 May; 51(5):1635-44. PubMed ID: 20196115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.